Ładuje się......
Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis
Progress in the development of new therapies for cystic fibrosis (CF) has benefitted from therapeutically responsive biomarkers to streamline drug development. Paradoxically, these response biomarkers have proven to be essential even in the presence of data demonstrating a lack of correlation with c...
Zapisane w:
| Wydane w: | Trends Mol Med |
|---|---|
| Główni autorzy: | , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
2020
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7708517/ https://ncbi.nlm.nih.gov/pubmed/32868171 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molmed.2020.08.002 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|